Literature DB >> 19464631

Therapeutic targets in malignant glioblastoma microenvironment.

Mary Helen Barcellos-Hoff1, Elizabeth W Newcomb, David Zagzag, Ashwatha Narayana.   

Abstract

There is considerable evidence that the tissue microenvironment can suppress cancer and that microenvironment disruption is required for cancer growth and progression. Distortion of the microenvironment by tumor cells can promote growth, recruit nonmalignant cells that provide physiological resources, and facilitate invasion. Compared with the variable routes taken by cells to become cancers, the response of normal tissue to cancer is relatively consistent such that controlling cancer may be more readily achieved indirectly via the microenvironment. Here, we discuss 3 ideas about how the microenvironment, consisting of a vasculature, inflammatory cells, immune cells, growth factors, and extracellular matrix, might provide therapeutic targets in glioblastoma (GBM) in the context of radiotherapy (RT): (1) viable therapeutic targets exist in the GBM microenvironment, (2) RT alters the microenvironment of tissues and tumors; and (3) a potential benefit may be achieved by targeting the microenvironments induced by RT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464631      PMCID: PMC3538148          DOI: 10.1016/j.semradonc.2009.02.004

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  99 in total

1.  Redox-mediated activation of latent transforming growth factor-beta 1.

Authors:  M H Barcellos-Hoff; T A Dix
Journal:  Mol Endocrinol       Date:  1996-09

Review 2.  The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

Authors:  M Weller; A Fontana
Journal:  Brain Res Brain Res Rev       Date:  1995-09

3.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

4.  Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.

Authors:  F M Kong; M S Anscher; T Murase; B D Abbott; J D Iglehart; R L Jirtle
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

5.  Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides.

Authors:  P Jachimczak; B Hessdörfer; K Fabel-Schulte; C Wismeth; W Brysch; K H Schlingensiepen; A Bauer; A Blesch; U Bogdahn
Journal:  Int J Cancer       Date:  1996-01-26       Impact factor: 7.396

6.  Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro.

Authors:  S Koochekpour; A Merzak; G J Pilkington
Journal:  Cancer Lett       Date:  1996-04-19       Impact factor: 8.679

7.  Short communication: normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGF beta.

Authors:  M S Anscher; F M Kong; T Murase; R L Jirtle
Journal:  Br J Radiol       Date:  1995-03       Impact factor: 3.039

8.  Transforming growth factor-beta in in vivo resistance.

Authors:  B A Teicher; S A Holden; G Ara; G Chen
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Maternal rescue of transforming growth factor-beta 1 null mice.

Authors:  J J Letterio; A G Geiser; A B Kulkarni; N S Roche; M B Sporn; A B Roberts
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

10.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors.

Authors:  P J Miettinen; R Ebner; A R Lopez; R Derynck
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  32 in total

1.  BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro.

Authors:  Jin Bai; Peng-Jin Mei; Hui Liu; Chen Li; Wang Li; Yong-Ping Wu; Zheng-Quan Yu; Jun-Nian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-24       Impact factor: 4.553

2.  A functional screen identifies miRs that induce radioresistance in glioblastomas.

Authors:  Patryk Moskwa; Pascal O Zinn; Young Eun Choi; Sachet A Shukla; Wojciech Fendler; Clark C Chen; Jun Lu; Todd R Golub; Anita Hjelmeland; Dipanjan Chowdhury
Journal:  Mol Cancer Res       Date:  2014-09-25       Impact factor: 5.852

3.  RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration.

Authors:  Peng-Jin Mei; Jin Bai; Hui Liu; Chen Li; Yong-Ping Wu; Zheng-Quan Yu; Jun-Nian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-16       Impact factor: 4.553

4.  CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages.

Authors:  Ayelet Levy; Eran Blacher; Hananya Vaknine; Frances E Lund; Reuven Stein; Lior Mayo
Journal:  Neuro Oncol       Date:  2012-06-14       Impact factor: 12.300

5.  Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Authors:  Kuan-Min Fang; Chung-Shi Yang; Tzu-Chien Lin; Ti-Chun Chan; Shun-Fen Tzeng
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

6.  Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.

Authors:  Caroline I Schnegg; Moon Hee Yang; Subrata K Ghosh; Mei-Yu Hsu
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

7.  Invariant delineation of nuclear architecture in glioblastoma multiforme for clinical and molecular association.

Authors:  Hang Chang; Ju Han; Alexander Borowsky; Leandro Loss; Joe W Gray; Paul T Spellman; Bahram Parvin
Journal:  IEEE Trans Med Imaging       Date:  2012-12-04       Impact factor: 10.048

Review 8.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

Review 9.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

10.  Inherited variation in immune genes and pathways and glioblastoma risk.

Authors:  Judith A Schwartzbaum; Yuanyuan Xiao; Yanhong Liu; Spyros Tsavachidis; Mitchel S Berger; Melissa L Bondy; Jeffrey S Chang; Susan M Chang; Paul A Decker; Bo Ding; Sarah J Hepworth; Richard S Houlston; Fay J Hosking; Robert B Jenkins; Matthew L Kosel; Lucie S McCoy; Patricia A McKinney; Kenneth Muir; Joe S Patoka; Michael Prados; Terri Rice; Lindsay B Robertson; Minouk J Schoemaker; Sanjay Shete; Anthony J Swerdlow; Joe L Wiemels; John K Wiencke; Ping Yang; Margaret R Wrensch
Journal:  Carcinogenesis       Date:  2010-07-28       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.